晚期黑色素瘤患者免疫相关不良事件管理与生存的关联
该基于人群的多中心队列研究纳入2015至2021年荷兰黑色素瘤治疗登记中一线伊匹木单抗联合纳武利尤单抗治疗后发生≥3级免疫相关不良事件的350例晚期黑色素瘤患者,比较单用类固醇与类固醇联合二线免疫抑制剂对生存的影响,发现二线免疫抑制与更差的PFS、OS和MSS相关。
要点
- 350例发生≥3级irAE的患者中,235例单用类固醇,115例类固醇联合二线免疫抑制剂。
- 单用类固醇组中位PFS为11.3个月,联合组为5.4个月,差异有统计学意义(P=0.01)。
- 校正混杂后,联合二线免疫抑制剂组死亡风险更高(校正HR 1.54,95%CI 1.03-2.30)。
核心结论
- 在晚期黑色素瘤患者中,一线伊匹木单抗联合纳武利尤单抗治疗后因irAE使用二线免疫抑制与PFS、OS和MSS受损相关。
研究设计与样本
- 基于人群的多中心队列研究,数据来自荷兰黑色素瘤治疗登记,纳入2015至2021年一线伊匹木单抗联合纳武利尤单抗治疗后发生≥3级irAE的晚期黑色素瘤患者350例,中位随访23.6个月。
主要发现
- 单用类固醇组中位PFS为11.3个月(95%CI 9.6-19.6),联合二线免疫抑制剂组为5.4个月(95%CI 4.5-12.4),P=0.01。
- 单用类固醇组中位OS为46.1个月(95%CI 39.0个月-未达到),联合组为22.5个月(95%CI 36.5个月-未达到),P=0.04。
- 单用类固醇组中位MSS未达到(95%CI 46.1个月-未达到),联合组为28.8个月(95%CI 20.5个月-未达到),P=0.006。
- 校正潜在混杂因素后,联合二线免疫抑制剂组进展风险呈升高趋势(校正HR 1.40,95%CI 1.00-1.97;P=0.05),死亡风险更高(校正HR 1.54,95%CI 1.03-2.30;P=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy. OBJECTIVE: To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy. DESIGN, SETTING, AND PARTICIPANTS: This population-based, multicenter cohort study included patients with advanced melanoma experiencing grade 3 and higher irAEs after treatment with first-line ipilimumab and nivolumab between 2015 and 2021. Data were collected from the Dutch Melanoma Treatment Registry. Median follow-up was 23.6 months. MAIN OUTCOMES AND MEASURES: The PFS, OS, and MSS were analyzed according to toxic effect management regimen. Cox proportional hazard regression was used to assess factors associated with PFS and OS. RESULTS: Of 771 patients treated with ipilimumab and nivolumab, 350 patients (median [IQR] age, 60.0 [51.0-68.0] years; 206 [58.9%] male) were treated with immunosuppression for severe irAEs. Of these patients, 235 received steroids alone, and 115 received steroids with second-line immunosuppressants. Colitis and hepatitis were the most frequently reported types of toxic effects. Except for type of toxic effect, no statistically significant differences existed at baseline. Median PFS was statistically significantly longer for patients treated with steroids alone compared with patients treated with steroids plus second-line immunosuppressants (11.3 [95% CI, 9.6-19.6] months vs 5.4 [95% CI, 4.5-12.4] months; P = .01). Median OS was also statistically significantly longer for the group receiving steroids alone compared with those receiving steroids plus second-line immunosuppressants (46.1 months [95% CI, 39.0 months-not reached (NR)] vs 22.5 months [95% CI, 36.5 months-NR]; P = .04). Median MSS was also better in the group receiving steroids alone compared with the group receiving steroids plus second-line immunosuppressants (NR [95% CI, 46.1 months-NR] vs 28.8 months [95% CI, 20.5 months-NR]; P = .006). After adjustment for potential confounders, patients treated with steroids plus second-line immunosuppressants showed a trend toward a higher risk of progression (adjusted hazard ratio, 1.40 [95% CI, 1.00-1.97]; P = .05) and had a higher risk of death (adjusted hazard ratio, 1.54 [95% CI, 1.03-2.30]; P = .04) compared with those receiving steroids alone. CONCLUSIONS AND RELEVANCE: In this cohort study, second-line immunosuppression for irAEs was associated with impaired PFS, OS, and MSS in patients with advanced melanoma treated with first-line ipilimumab and nivolumab. These findings stress the importance of assessing the effects of differential irAE management strategies, not only in patients with melanoma but also other tumor types.
引用
- van Not OJ, Verheijden RJ, van den Eertwegh AJM, et al. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. JAMA Oncol. 2022. PMID: 36301521. doi:10.1001/jamaoncol.2022.5041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。